Please assess the completion status of the following clinical trial:

Trial Title: Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with postmenopausal osteoporosis diagnosed by DXA scanning, defined by T-score of -2.5 SD at spine or femur.~* Patients who have never received bisphosphonates therapy (bisphosphonates naive)~Exclusion Criteria:~* Inability to stand or sit in the upright position for at least 60 minutes;~* Hypersensitivity to any component of risedronate and ibandronate;~* Administration of any investigational drug within 30 days preceding the first dose of the study drug;~* Patient has been on hormone (estrogen) replacement therapy or other osteoporosis medication (e.g. SERMS and calcitonin) within the previous 3 months.~* Patient has been on systemic corticosteroids therapy for more than 1 month within the past year.~* Other bone disease except osteoporosis~* Current medical history of uncontrolled major upper GI disease

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).